Market open
Immunic/$IMUX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Ticker
$IMUX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
91
ISIN
US4525EP1011
Website
Immunic Metrics
BasicAdvanced
$95M
-
-$1.00
1.73
-
Price and volume
Market cap
$95M
Beta
1.73
52-week high
$1.84
52-week low
$0.83
Average daily volume
1.1M
Financial strength
Current ratio
1.774
Quick ratio
1.639
Long term debt to equity
1.433
Total debt to equity
5.448
Management effectiveness
Return on assets (TTM)
-128.79%
Return on equity (TTM)
-424.44%
Valuation
Price to book
4.87
Price to tangible book (TTM)
4.87
Price to free cash flow (TTM)
-1.173
Growth
Earnings per share change (TTM)
-52.50%
3-year earnings per share growth (CAGR)
-36.56%
What the Analysts think about Immunic
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immunic stock.
Immunic Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immunic Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immunic News
AllArticlesVideos
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
Proactive Investors·2 weeks ago
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Seeking Alpha·3 weeks ago
Immunic announces pricing of $5.1M direct offering to support clinical pipeline
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immunic stock?
Immunic (IMUX) has a market cap of $95M as of May 16, 2025.
What is the P/E ratio for Immunic stock?
The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of May 16, 2025.
Does Immunic stock pay dividends?
No, Immunic (IMUX) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Immunic dividend payment date?
Immunic (IMUX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunic?
Immunic (IMUX) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.